Mon, October 18, 2021
Sun, October 17, 2021
Fri, October 15, 2021
Thu, October 14, 2021
Wed, October 13, 2021
Tue, October 12, 2021
Mon, October 11, 2021
Sun, October 10, 2021
Fri, October 8, 2021
Thu, October 7, 2021

David Macdonald Maintained (AMED) at Strong Buy with Decreased Target to $190 on, Oct 13th, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-190-on-oct-13th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

David Macdonald of Truist Securities, Maintained "Amedisys, Inc." (AMED) at Strong Buy with Decreased Target from $255 to $190 on, Oct 13th, 2021.

David has made no other calls on AMED in the last 4 months.



There are 9 other peers that have a rating on AMED. Out of the 9 peers that are also analyzing AMED, 4 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whit Mayo of "SVB Leerink" Initiated at Hold and Held Target at $170 on, Monday, September 27th, 2021
  • Gary Taylor of "Cowen & Co." Initiated at Hold and Held Target at $195 on, Friday, September 10th, 2021
  • Scott Fidel of "Stephens & Co." Maintained at Hold with Decreased Target to $237 on, Friday, August 6th, 2021
  • Joanna Gajuk of "B of A Securities" Downgraded from Strong Buy to Hold and Held Target at $220 on, Thursday, August 5th, 2021


These are the ratings of the 5 analyists that currently disagree with David


  • Andrew Mok of "UBS" Initiated at Strong Sell and Held Target at $150 on, Friday, September 24th, 2021
  • A.J. Rice of "Credit Suisse" Maintained at Buy with Decreased Target to $250 on, Wednesday, August 11th, 2021
  • John Ransom of "Raymond James" Maintained at Buy with Decreased Target to $250 on, Tuesday, August 10th, 2021
  • Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $235 on, Tuesday, August 10th, 2021
  • Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $265 on, Friday, August 6th, 2021

Publication Contributing Sources